Home
overview
SMi presents their inaugural conference on...
 
 
 Biobanking
 
 
London, 11th & 12th July 2011
 
SMi's Biobanking  is the perfect opportunity to network with the industry’s leading figures and contribute to the successful future of drug discovery. With a key focus on bridging the gap between the world’s leading academia and the pharma industry, Biobanking provides the perfect forum to successfully build essential frameworks for future research and drug development.
 
Developing communication frameworks between academics and pharmaceutical companies should not be underestimated as R&D undertaken by leading academics delivers huge value and importance to future drug development. It is in the commercial interest of leading pharmaceutical companies to build frameworks to not only harmonise and standardize biobanks on a global scale, but to ensure communication between universities and pharma are in place. By working together and understanding each other’s needs will mean the quality and diversity of samples and research will attract continual financial rewards for future drug development.
 
Academia 
With a programme full of leading academic institutions such as the Royal Liverpool University Hospital, National Cancer Institute and  Cancer Research UK pharmaceutical companies Biobanking provides a fantastic opportunity for building and developing frameworks with these leading organizations
 
Pharma
With Genzyme, GSK, AstraZeneca, Genentech,Sanofi-Aventis and Merck all attending, take advantage of this opportunity to create and develop commercial strategies for future drug discoveries 
 
The conference will focus on main areas of:
  • Enforcing standardisation on global scale
  • Utilising biobanks for research and development
  • The impact of sample type and DNA concentration on experimental Genotyping outcomes
  • Regenerative medicines - putting it all into practice
  • Implementing and developing new technologies within biobanking
  • Managing biobanks - overcoming issues and plans for future demand
  • Informatics: as good as paper?
     
 
 

SMi's inaugural Biobanking conference offers an unparalleled opportunity to learn about the developments in R&D markets.

Book today to:

  • Hear the very latest research from top pharmacutical companies
  • Understand market conditions for both clinical and commercial growth
  • Improve your collection by developing  frameworks for quality sample management
  • Participate in interactive discussions and our fantastic post-conference workshop
  • Develop and implement innovative technologies within biobanking
  • Gather information vital to the success of your business
  • Enjoy excellent networking opportunities with leading industry colleagues

With a fantastic mix of top level pharma companies, leading academic instiutions and new upcoming biobanks from across Europe and the US, SMi's Biobanking focuses on attracting investment; the key to future biobanking.

 Delegates who can benefit from this event include:

VP's, DIrectors, Head and Managers from:

  • Independent Biobanks
  • Pharmaceutical
  • Biotech
  • Medical Research Institutes
  • Academics
  • Tissue  Banks

In the following departments:

  • R&D
  • Biobanking
  • Biorepository
  • Biological Sample management
  • Biosample Management
  • Pharmacogenomics
  • Genomics
  • Translational Medicine 
  • Personalised medicine
  • Scientific and Quality
  • Laboratory and Inventory
  • Quality and Control
  • Strategic Outsouring
  • Business Development
  • Data protection

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Rivka Ravid

Rivka Ravid, Consultant on Brain Banking, Netherlands Institute for Neurosciences

9:10 The pitfalls and practicalities in the daily practice of Brain Banks for biomedical research

Rivka Ravid

Rivka Ravid, Consultant on Brain Banking, Netherlands Institute for Neurosciences

Drug Discovery in neurological disorders heavily relies on well designed and accessible brain banks and the specimens they contain, how they’ve been stored and annotated and the quality of accompanying clinical and pathological data. 

• Describing who is involved, responsible and benefiting from successful brain banking repositories
• Researchers input /demand to specimens needed and how to access them
• Clinical assessment and viability of samples
• Importance of electronic tracking of samples to ensure maximise use
• Examples of successful studies of Biomarkers discovery
• Ethical code of conduct for Brain banks and genetic screening.
 

9:50 Public - Private Partnerships in Biobanking: UK PLC?

Julie Corfield

Julie Corfield, Head of Biobank, AstraZeneca

• What does this mean?
• Why, and the potential impact on unmet need
• Ethical and operational aspects of optimising the use of human samples

10:30 Morning Coffee

11:00 Panel Discussion: Academia and Pharma: A collaborative approach to biobanking

• Virtual Biobanking: Improving collaborations
• Developing communication frameworks between universities and banks
• Institutions and pharma working together in R&D
 

Daniel Brewer

Daniel Brewer, Biobank Lead Developer, Institute of Cancer Research

Rivka Ravid

Rivka Ravid, Consultant on Brain Banking, Netherlands Institute for Neurosciences

Julie Corfield

Julie Corfield, Head of Biobank, AstraZeneca

11:40 The impact of sample type and DNA concentration on experimental genotyping outcomes

David  Pulford

David Pulford, PGx Capabilities EU & International, GlaxoSmithKline

• Viable DNA samples are essential for genetics research
• Sample collection variables and the resulting impact on genotyping call rate will be considered
• How do low concentration DNA samples perform on genotyping platforms?

12:20 Networking Lunch

13:20 Case Study: Biobank of pancreas in clinical trials

Bill Greenhalf

Bill Greenhalf , Liverpool Experimental Cancer Medicine Centre and NIHR Pancreatic Biomedical Research Unit, GCLP facility

  • The legal requirements for storage and assay of trial material
  • The need for audit from the consent form through the storage and to the data generated from samples
  • Validation of assays
  • Use of LIMS to aid inspection
  • 14:00 Research and Development: Stem Cell Banking

    Glyn Stacey

    Glyn Stacey, Director of the UK Stem Cell Bank, National Institute For Biological Standards And Control

  • Examining the latest developments in stem cell banking
  • Utilising biobanks to research future discoveries
  • Issues with collecting and storing samples
  • Stem cell banking under quality standards
  • 14:40 Global regulations: What are the commercial opportunities

    Lincoln Tsang

    Lincoln Tsang, Partner, Arnold and Porter

    • Understanding the international framework of regulations: What is the current climate
    • What regulatory demands will there be in future biobanking
    • Examining bioethics for the global biobanking field
    • Variants of local requirements
    • Legal and ethical issues with ownership and commercialisation

    15:20 Afternoon Tea

    15:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    George   Tokiwa

    George Tokiwa, Associate Scientific Director, Merck Research Laboratories

    9:10 Importance of sample quality in creating a valuable biobank

    Diane Leong

    Diane Leong, Associate Director, Genentech

    • Increasing standards
    • Issues with collecting high-quality samples
    • How are companies tackling issues in collecting samples?
    • Future challenges in collecting samples

    9:50 Standardising biobanks to increase quality outcomes and developments

    Helen Moore

    Helen Moore, Biospecimen Research Network Program Manager , National Cancer Institute

  • Establishing polices for biospecimen quality in biobanks
  • Tracking operations
  • Controlling the issue of ethics
  • Standardising the process for collecting samples
  • Sample collections process improvements
  • 10:30 Morning Coffee

    11:00 Informatics: How to manage my biobank and my database

    Anne Bahr

    Anne Bahr, Data Protection Officer, Sanofi-Aventis

    How and where should results be stored?
    How to ensure that samples and data can be re-used?
    When should double-coding be used? How to proceed in practice?
    What should I do with data and sample in case of withdrawal?

    11:40 When failure is not an option: Ensuring biospecimen integrity and data security in an automated biorepository environment

    Johann van Niekerk

    Johann van Niekerk, Product Manager Biostorage, Nexus Biosystems

  • Critical Sample Audit Trail Management
  • Processing Biological Samples
  • Information Management Solutions in an Automated Environment
  • 12:20 Networking Lunch

    13:30 Implementing and developing technologies within biobanking

    Anna Beskow

    Anna Beskow, Head and Chief Biobank Officer , Uppsala Biobank

    • Limitations of LIM System: Standardising the systems for biobank sample management
    • Sample tracking: Ensuring quality management of samples
    • Semi automated system for hospital integrated biobanking
    • How can professional biobanking as a service attract attention

    14:10 Creating new opportunites on a global scale

    George   Tokiwa

    George Tokiwa, Associate Scientific Director, Merck Research Laboratories

    • Benefits of pharmaceutical companies and biobanks moving towards global healthcare cooperation
    • Developing a unified model for maintaining high quality samples and generating innovative R&D
    • Consolidating biobanking practices globally
    • Importance of following standard procedures regarding consent and quality of samples

    14:50 Afternoon Tea

    15:10 Communications, transparency and accountability – the cornerstones to responsible biobanking

    Brian Clark

    Brian Clark, Managing Director, Biobank Qatar for Medical Research

    • Planning and implementation for biobanks often focuses on issues with a technical, technological or scientific focus. Broader context “human” issues are often of lower priority.
    • Successful and responsible biobanking takes account of the position and role of the biobank in the society within which it exists, not just the scientific aspects.
    • Communications, transparency and accountability are key to fulfilling the role of the biobank in society.

    15:50 Chairman’s Closing Remarks and Close of Day Two

    +

    Workshops

    Operating Biobanks: The practicalities in developing R&D
    Workshop

    Operating Biobanks: The practicalities in developing R&D

    Crowne Plaza - The City
    13th July 2011
    London, United Kingdom

    Crowne Plaza - The City

    19 New Bridge Road
    London EC4V 6DB
    United Kingdom

    Crowne Plaza - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.